Answers are grounded in this paper and cite their sources.
Case series reports rituximab improves outcomes for severe immune checkpoint inhibitor-related adverse events, suggesting effective B-cell therapy.
Rituximab appears to be an effective therapeutic option for selected severe ICI-related irAEs, particularly when conventional immunosuppressive regimens fail. These real-world data highlight the potential role of B-cell-targeted therapy in the management of complex irAEs and support further evaluation in prospective studies.
No takes yet. Share an insight, caveat, or question.
Hermabessiere et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: